- MRK -0.42%
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Yahoo Finance · 17 hours ago
Open | 128.61 |
High | 129.69 |
Low | 127.99 |
Mkt Cap | 324.89B |
P/E (TTM) | 142.51 |
Div & Yield | 3.08 & 2.40% |
Prev. Close | 128.80 |
52 Wk. Low | 99.14 |
52 Wk. High | 133.10 |
Related stocks
American multinational pharmaceutical company
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 15.78B | 8.90% ▲ |
Net Income | 4.76B | 68.80% ▲ |
Diluted EPS | 2.07 | 68.50% ▲ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $2.14 | - |
Q1 2024 | $1.87 | $2.07 |
Q4 2023 | -$0.11 | $0.03 |
S&P FuturesES=F | 5,112.00+20.50 (+0.40%) |
Dow FuturesYM=F | 38,688.00+306.00 (+0.80%) |
Nasdaq FuturesNQ=F | 17,769.75+120.00 (+0.68%) |
Apple Inc.AAPL | 173.03+2.20% |
Amgen Inc.AMGN | 278.39+0.37% |
228.85+8.93% |